Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates

Group 1 - Dare Bioscience, Inc. reported a quarterly loss of $0.55 per share, better than the Zacks Consensus Estimate of a loss of $0.60, and an improvement from a loss of $1.08 per share a year ago, representing an earnings surprise of 8.33% [1] - The company posted revenues of $0.04 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 98.64%, and down from $1 million in the same quarter last year [2] - Dare Bioscience shares have increased by approximately 3.4% since the beginning of the year, while the S&P 500 has gained 25.5% [3] Group 2 - The earnings outlook for Dare Bioscience is mixed, with the current consensus EPS estimate for the coming quarter at -$0.39 on revenues of $4.19 million, and -$0.27 on revenues of $3.67 million for the current fiscal year [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 29% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]